Clinical trial · Interventional
Cancer, Nutrition and Taste
Impact of a Food Improvement Strategy on Their Appreciation in a Population of Cancer Patients Treated With Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer promotes weight loss; it can also lead to particular complications for patients during treatment. A team led by Dr Michael Sawyer, showed the deleterious impact of undernutrition on the benefits of chemotherapy. Cancer patients are at high risk of undernutrition, which is generally more pronounced for solid tumours (upper digestive tract, ENT, bronchial tubes…). This undernutrition leads to major weight loss and wasting, and may represent the first sign of a call for a diagnosis of cancer. Cancer-related undernutrition is multi-factorial in origin and has multiple consequences; it has its own prognostic value. Chemotherapy treatments can induce various adverse effects in patients, including sensory disturbances at the beginning of treatment in addition to disturbances that may already be present before any treatment. Altered taste and odour, observed in 86% of patients, can induce a change in food preferences, promote the development of aversions, and therefore, lead to a significant reduction in the pleasure of eating. Loss of appetite, decreased food intake and the development of aversions to certain foods are situations experienced by a large proportion of patients undergoing chemotherapy. The assessment of taste disorders in patients undergoing chemotherapy treatment is established through the use of questionnaires, interviews and taste tests. Changes in the perception and identification of salty, sweet, bitter and sour flavours are common in patients undergoing chemotherapy. The objective of CANUT is to study the effect of pathology and chemotherapy on gustatory and olfactory mechanisms and in particular on interindividual differences in the perception and appreciation of food. In this study the investigators propose to adapt foods to best respond to sensory disorders related to the disease and/or treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Nutrition Disorders | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adapted food intervention | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention arm
- description
- At each meal: different elements will be presented to the patient (starter / main course / side dish / dessert). For each of these elements, the patient will be offered 4 versions (a standard version and 3 adapted versions of the same food): * The standard food. * The food refers to a more elaborate texture. * The food refers to a food with a stronger smell. * The food refers to a more important flavor. The patient will indicate the version of the food that will be preferred.
- interventionNames
- Dietary Supplement: Adapted food intervention
Primary outcomes (1)
- measure
- proportion of treated patients by 4 cycles of chimiotherapy that will prefere at least 1 modified version of meal.
- timeFrame
- 12 weeks
- description
- The main endpoint of the CANUT-1 study is the proportion of cancer patients treated with chemotherapy (after 4 cycles) who will prefer at least an adapted version of a food compared to the standard version of the same food.
Secondary outcomes (12)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with advanced lung cancer requiring a first line of intravenous chemotherapy or patient with localized, histologically or cytologically proven breast cancer for whom intravenous chemotherapy treatment will be initiated or patient with stage III-IV gynecological cancer (ovarian cancer or uterine cancer) for whom intravenous chemotherapy treatment will be initiated. * Patient with a body mass index (BMI) between 18Kg/m² and 35Kg/m². * Patient whose indication for treatment with intravenous chemotherapy has been selected * Naive patient of previous chemotherapy. * Life expectancy \> 3 months. * Patient able to travel for 4 visits to the Paul Bocuse Institute, 1 Chemin de Calabert, 69 130 ECULLY, FRANCE. * Written informed consent obtained in accordance with applicable GCPs. * Patients affiliated to a social security system. * Patients who have the possibility of being accompanied, by the same person, to the visits of the test meals at the Paul Bocuse Research Institute Exclusion Criteria: * Patient under 18 years of age. * Patient who has had another malignant tumor in the last 3 years. * Patient with symptomatic brain metastases. * Patient with symptomatic mucositis. * Patient suffering or having suffered from an otorhinolaryngic or oesogastrointestinal pathology interfering with food intake. * Patients with digestive disorders before any cancer treatment. * Indication for concomitant radiotherapy or immunotherapy alone treatment. * Patient with a known food allergy or food intolerance. * Patient with partial or total agueusia diagnosed. * Patient with diagnosed partial or total anosmia. * Patients who have used artificial feeding within 2 months. * Patients who have lost more than 10% of their baseline weight within 2 months. * Patient unable to be regularly monitored for any reason * Patient deprived of liberty or placed under guardianship or curatorship * Pregnant or breastfeeding patient.
References
Publications (0)
Data not yet available